Celon Pharma S.A. (WSE: CLN)

Market Cap	1.47B
Revenue (ttm)	206.81M
Net Income (ttm)	-45.48M
Shares Out	53.86M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	0.08 (0.29%)
Ex-Dividend Date	Jun 27, 2024

Volume	43,551
Open	27.35
Previous Close	27.60
Day's Range	27.00 - 28.05
52-Week Range	14.00 - 32.90
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2024

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 515
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2023, Celon Pharma's revenue was 213.92 million, an increase of 10.33% compared to the previous year's 193.89 million. Losses were -28.12 million, -28.40% less than in 2022.